Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

Lantheus and Point Biopharma shares drop on prostate cancer treatment data

Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15

Eli Lilly extends tender offer to buy Point Biopharma after low participation

Eli Lilly to Buy Point Biopharma for $1.4 Billion

Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion

Point Biopharma Global's stock jumps more than 80% after Lilly merger deal